CONCLUSIONS: Quadrivalent seasonal influenza vaccines, at price parity with trivalent vaccines, appear to be highly cost-saving from the third-party payer and the societal perspectives. 
OBJECTIVES:
To determine the incremental cost-effectiveness of linezolid versus vancomycin using data from a clinical trial assessing treatment of nosocomial pneumonia due to MRSA in hospitalized adults. METHODS: A cost-effectiveness analysis from the U.S. hospital-payer perspective was piggybacked onto a phase 4, randomized, double-blind, multicenter trial (Wunderink et al, Clin Infect Dis 2012) in nosocomial pneumonia patients with culture-proven MRSA [microbiologic confirmed intent-to-treat (mITT) cohort]. Efficacy was measured by treatment success (defined as Cure+Improvement) at the end of study (i.e., 7-30 days after the end of treatment). Direct medical costs (USD, 2011 values) were calculated from the health care resources used, including study medication, hospitalization, mechanical ventilation, and dialysis. Nonparametric bootstrapping was conducted to calculate confidence intervals (CI) for costs, efficacy, and incremental cost-effectiveness ratios (ICER). One-way sensitivity analyses were conducted to evaluate the uncertainty and cost drivers. RESULTS: Data from 391 patients (186 linezolid, 205 vancomycin) were analyzed. A greater proportion of linezolid patients achieved treatment success versus vancomycin patients [mean (95% CI)]: 55% (48.3%-61.9%) versus 45% (38%-52.3%). Total costs per linezolid patient were $48,929 ($45,375-$52,483) compared to $46,665 ($43,201-$50,128) per vancomycin patient. The point estimate for the ICER of linezolid versus vancomycin was $16,516. The median ICER from bootstrapping was $16,219 (95% percentile: $100,487). Of the 10,000 bootstrap simulations, 73% had greater efficacies and higher costs (positive ICERs) for linezolid, 24% had greater efficacies and lower costs for linezolid (linezolid dominated vancomycin), and <2% had greater efficacies and lower costs for vancomycin (vancomycin dominated linezolid). Key cost drivers included number of ICU and general ward days in each treatment group. Addition of empirical treatment had a relatively small impact on ICER. CONCLUSIONS: In this clinical trial population, linezolid appears to be cost-effective compared to vancomycin in treating patients with nosocomial pneumonia due to MRSA. Previous study has shown that Posaconazole is cost-effective versus FLU/ITRA in the 2007 U.S. health care setting.To reflect the changes in health care cost and the changes in drug prices, the study aims to provide an update on the costeffectiveness of Posaconazole in the current U.S. health care setting. METHODS: A previously published (O'Sullivan et.al., VIH 2009) cost effectiveness model was used to assess the cost-effectiveness of posaconazole versus FLU/ITRA in the prevention of IFIs among patients with neutropenia resulting from chemotherapy for AML or MDS. Drug efficacy, mortality related to IFIs and death from other causes, were all estimated using data from a randomized clinical trial (Cornely et.al., NEJM 2007) . IFI treatment costs were inflation-adjusted over last 6 years (2007) (2008) (2009) (2010) (2011) (2012) and drug costs were based on 2012 IMS data. RESULTS: Trial data estimates the probability of an IFI over 100 days of follow-up while on Posaconazole to be lower than FLU /ITRA (0.05 vs. 0.11).The duration of treatment on Posaconazole is 25 days compared to 29 days with FLU or ITRA. Total costs of prophylaxis with FLU /ITRA and posaconazole is $5,293 and $5,859 respectively. The incremental cost-effectiveness ratios (ICER) for Posaconazole versus FLU/ITRA are estimated to be $8,805 per IFI avoided and $8,439 per life-year saved. CONCLUSIONS: Posaconazole is cost-effective to FLU or ITRA in the prevention of IFIs among neutropenic patients with AML and MDS in the current U.S. health care setting. 
PIN65 COST-EFFECTIVENESS OF POSACONAZOLE VERSUS FLUCONAZOLE OR ITRACONAZOLE IN THE PREVENTION OF INVASIVE FUNGAL INFECTIONS AMONG NEUTROPENIC PATIENTS IN THE UNITED STATES

PIN66 POTENTIAL EPIDEMIOLOGICAL AND ECONOMIC IMPACT OF DIFFERENT ROTAVIRUS VACCINES IN LOW AND MIDDLE INCOME COUNTRIES
OBJECTIVES:
Several studies have shown rotavirus vaccine is cost effective in low and middle income countries. Despite this, competing choices of rotavirus vaccines make the selection of either vaccine difficult for health decision-makers in low resource settings. The objective of this study is to assess cost effectiveness of the monovalent (MNV) and pentavalent (PTV) rotavirus vaccines on children mortality in 116 low and middle income countries that represent ~99% of rotavirus mortality. METHODS: A decision economic model was built to estimate the effect of MNV or PTV vaccination. Inputs were gathered from international databases, previous research and a systematic review of MNV and PTV vaccine effectiveness. Outcomes were reported in terms of cost per disability-adjusted life-year (DALY) averted, comparing no vaccination being implemented on selected countries for the year 2010 with either MNV or PTV introduction. Costs were expressed in 2010 international dollars. RESULTS: Low and middle income countries would have had 601,511 deaths in 2010, if rotavirus vaccine would not have been used. Under no vaccine scenario, 139 DALYs per 1000 children, 1.57 million inpatient and 9.17 million outpatient cases would occur every year. MNV would avert 53.3% of rotavirus-related deaths, and PTV 57.9%. MNV and PTV were highly cost effective worldwide, according to WHO criteria (less than per capita gross domestic product). I$143 cost per DALY for MNV versus I$152 cost per DALY for PTV. Uncertainty was lower in low income countries. CONCLUSIONS: Rotavirus vaccine is cost-effective in all analyzed countries. Despite cost effectiveness analysis is a useful tool for decision making in middle income countries, for low income countries health-decision makers should also assess the impact of introducing either vaccine on local resources, and budget impact analysis of vaccination. 
PIN67 COST-EFFECTIVENESS EVALUATION OF AMPHOTERICIN B, AMPHOTERICIN B LIPOSOMAL, CASPOFUNGIN AND VORICONAZOL IN TREATING ASPERGILLOSIS UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
OBJECTIVES:
Aspergillosis is the second cause of invasive fungal infections with high mortality rates. The objective of this research is to evaluate the costeffectiveness of amphotericin B(AB) 1.5mg/kg/day, amphotericin B liposomal(AL) 3mg/kg/day, caspofungin(CA) 50mg/day, voriconazol 8mg/kg/day(VO) including maintenance oral Voriconazol 400mg/day scheme in the treatment of aspergillosis under the Brazilian private health care system perspective. METHODS: A decision tree model was built considering sequential treatments, from which patients could respond to one initial treatment and continue to a maintenance phase of the same medication, or do not respond due to either inefficacy or adverse events and switch treatments with assumed equal chance to use one of the other options. Effectiveness measures were mortality, clinical response and days of hospitalization, calculated by indirect comparison of a literature systematic review. Only direct costs were considered, and were obtained from CFM/CBHPM2010 for medical procedures, MOH/CMED December2012 price list for medications, and BRASINDICE for materials. Values were represented in 2012USD. A time horizon no longer than 4 weeks was considered, thus discounting was not applied. One-way sensitivity analysis considered de-hospitalization in maintenance phases while using oral voriconazol. RESULTS: Clinical response rates were 36.40%(AB), 34.60%(AL), 34.20%(CA), 56.67%(VO), mortality rates were 50.90%(AB), 48 
Brazilian 2011GDP per capita), VO was the only cost-effective option compared to AB, additionally presenting lower mortality and less hospitalization days while allowing early de-hospitalization at private health care services. 
PIN68 IMPACT OF VACCINATION COVERAGE ON COST-EFFECTIVENESS OF INFLUENZA VACCINE AT PREVENTING HOSPITALIZATION
OBJECTIVES:
Influenza results in excess morbidity and mortality and therefore causes significant burden in a society. Outcomes of the influenza vaccination program are influenced by patient acceptance to receive the vaccine. The costeffectiveness of influenza vaccine at preventing hospitalization for lower respiratory infections in Hong Kong was examined at different levels of vaccination coverage. METHODS: A decision model was designed to simulate the outcomes of influenza vaccination programs at four different levels of vaccination coverage in a hypothetical cohort of elderly aged 65-year-old or above who have with no contraindications for influenza vaccine: 1) 16% (current vaccination coverage rate in Hong Kong); 2) 35% (vaccination coverage rate in some Asian countries; 3) 65%; and 4) 100%. The time horizon was one year. Model inputs were derived from literature, and outcome measures were direct medical cost (including vaccination) from the health care provider's perspective, influenza-associated mortality rate, and quality-adjusted life-year (QALY) gained. Robustness of model results was examined by sensitivity analysis. RESULTS: In the base-case scenario, 100% vaccination coverage was associated with the lowest cost (USD6.92), the lowest influenza-associated mortality rate (0.30 deaths per 10,000 persons) and the highest QALYs gained (0.8358), followed by 65% coverage rate (USD8.08; 0.35 deaths per 10,000 persons; 0.8351 QALYs), 35% coverage rate (USD9.07; 0.39 deaths per 10,000 persons; 0.8345 QALYs) and 16% rate (USD9.70; 0.42 deaths per 10,000 persons; 0.8342 QALYs). The results were robust to variation of all model inputs in sensitivity analysis. CONCLUSIONS: In the present model, high coverage rate of influenza vaccination seems to be associated with lower direct medical cost, lower influenza-associated deaths and higher QALYs. 
PIN69 THE COST-EFFECTIVENESS OF HEPATITIS B VACCINATION USING HEPLISAV VERSUS ENGERIX-B IN SELECT ADULT POPULATIONS IN THE UNITED STATES
OBJECTIVES: HEPLISAV is an investigational hepatitis B virus (HBV) vaccine with
an adjuvant that specifically targets toll-like receptor 9 and in clinical studies provided more rapid and higher rates of seroprotection with fewer doses compared with currently available vaccines. We modeled the cost-effectiveness of vaccination with HEPLISAV compared with Engerix-B in the prevention of HBV infection in select adult populations. METHODS: A Markov model was developed for each population of interest: diabetics, patients with chronic or end stage kidney disease, health care workers and international travelers to countries with high HBV infection prevalence. Disease progression was modeled using 11 health states: seroprotected, susceptible, acute infection, chronic infection, fulminant hepatic failure, compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, liver transplant, post-transplant care, and death. Seroprotection rates were based on results from two phase 3 clinical trials comparing HEPLISAV with Engerix-B and ranged across the various populations from 89-96% for HEPLISAV and 62-81% for Engerix-B. Higher vaccination completion rates were assumed for HEPLISAV compared with Engerix-B given that fewer doses of HEPLISAV are required in a shorter period of time to achieve seroprotection for the evaluated populations. Each cycle length represented a 1-year time frame. All future costs and benefits were discounted at 3%. A lifetime analysis and a U.S. payer perspective were used in this study. RESULTS: HEPLISAV has a favorable costeffectiveness profile with incremental cost-effectiveness ratios <$20,000 across all populations studied. In the patients with chronic or end stage kidney disease, HEPLISAV was the dominant option and was cost-saving compared with Engerix-B. The cost of vaccine, regimen completion rates, and seroprotection rates were the sensitive variables in the models. CONCLUSIONS: HEPLISAV may be a costeffective option for HBV vaccination to provide high rates of seroprotection and early seroprotection across a range of populations from health care workers to patients with chronic or end stage kidney disease. BACKGROUND: For first-line HIV treatment, US treatment guidelines state that efavirenz (EFV) is the only preferred non-nucleoside reverse transcriptase inhibitor (NNRTI) while nevirapine (NVP) is listed as an acceptable NNRTI. Generic versions of NVP were first approved in the US in May 2012. OBJECTIVES: To assess the cost-effectiveness of EFV compared with generic NVP in first-line HIV treatment in the US. METHODS: A micro-simulation state transition model was constructed to estimate the costs (2012 US$) and clinical outcomes for antiretroviral naïve HIV patients initiating EFV or NVP. Efficacy and safety data was based on the HIV Causal Collaboration Study and a Cochrane Review. Published sources were used to identify other inputs. Costs included antiretroviral drug acquisition, disease management (based on CD4 counts) and adverse events. Health utility was based on CD4 counts and adverse events. A 3% discount rate was used for costs and quality-adjusted life years (QALYs). Results are based on 100,000 micro-simulation trials with a ten year time horizon. RESULTS: Over a 10-year period, EFV was dominant over NVP in the base case with lower total costs ($346,932 vs. $364,475), modestly higher QALYs (6.795 vs. 6.782), and similar life expectancy (9.346 vs. 9.342 years). Keeping all other inputs constant, EFV was dominant over generic NVP until the price of NVP was reduced to 50% of its base case value. Giving EFV and NVP equal probability of treatment success but maintaining basecase adverse event rates and costs resulted in an incremental cost effectiveness ratio of $4,438 for EFV compared to NVP. CONCLUSIONS: Over a 10-year time horizon, EFV was predicted to be costsaving compared to generic NVP with modestly higher QALYs and similar life expectancy in HIV patients initiating first-line treatment in the US. Sensitivity analysis indicated results were not sensitive to NVP price changes. OBJECTIVES: Skin and soft tissue infections caused by Staphylococcus aureus and Streptococcus pyogenes are a growing concern in Latin America due to the development of more complex resistance profiles to standard antibiotics. The aim of this analysis is to estimate the cost-effectiveness of Linezolid in the treatment of complicated skin and soft tissue infections (cSSTI) in Colombia. METHODS: A decision tree was built to estimate the incremental costeffectiveness ratio of the Linezolid (600 IV/twice day) switch (600 orally/twice day) compared to Vancomycin (1 g IV/twice day), Daptomycin (4 mg IV/kg/day) and Tigecycline (100 mg IV followed by 50 mg twice day). The perspective was third payer including direct medical costs only. Effectiveness, safety and utility data were extracted from published literature. Unit costs were taken from health care institutions. Resource use and costs (drug acquisition, inpatient stay, health care professional visits, and lab tests) were considered for the model and expressed in 2012 US$. Time horizon was 28 days and effectiveness measures were quality-adjusted life-year (QALY's) and percentage of patients cured. OBJECTIVES: For first-line treatment of HIV, US treatment guidelines recommend the once-daily tablet of efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF) as a preferred regimen and the once-daily tablet of elvitegravir/cobicistat/emtricitabine/tenofovir (EVG/cobi/FTC/TDF) as an alternative regimen. This study assessed the clinical and economic trade-offs involved in using EVG/cobi/FTC/TDF compared with EFV/FTC/TDF in first-line HIV antiretroviral therapy (ART) in US adults. METHODS: A Markov cohort model was developed to project lifetime health-related outcomes, costs, qualityadjusted life years (QALYs), and cost-effectiveness of EVG/cobi/FTC/TDF compared with EFV/FTC/TDF as first-line ART in the US. HIV patients progressed in 12-week cycles through second-line, third-line, and non-suppressive therapies, AIDS, and death. Baseline characteristics and first-line virologic suppression, change in CD4 count, and adverse effects (lipid, central nervous system, rash, and/or renal) were based on 48-week clinical trial results. These results demonstrated equivalent virologic suppression between the two regimens. Point estimates for virologic suppression (favoring EVG/cobi/FTC/TDF) were used in the base case, and equivalency in scenario analysis. Published sources and expert opinion were used to estimate costs, utilities, AIDS risk, mortality, and subsequent-line CD4 count, efficacy and adverse events. Costs were reported in 2012 US dollars. Sensitivity analyses were conducted to assess robustness of results. RESULTS: Compared with patients initiating EFV/FTC/TDF, patients initiating EVG/cobi/FTC/TDF were estimated to have higher lifetime costs. EVG/cobi/FTC/TDF added 0.087 QALYs over a lifetime at a cost of $10,843, producing an incremental cost-effectiveness ratio of $124,101/QALY gained. Results were most sensitive to first-line response, product costs, and likelihood of renal adverse events. When equivalent efficacy was assumed, EFV/FTC/TDF dominated EVG/cobi/FTC/TDF with lower costs (-$12,305) and greater QALYs (0.047). CONCLUSIONS: At a societal willingness to pay of $100,000/QALY, EVG/cobi/FTC/TDF was not cost effective in the base case compared with
PIN70 COST-EFFECTIVENESS OF EFAVIRENZ COMPARED WITH GENERIC NEVIRAPINE IN HIV PATIENTS INITIATING FIRST-LINE TREATMENT IN THE UNITED STATES
PIN71 COST-EFFECTIVENESS ANALYSIS OF LINEZOLID IN THE TREATMENT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS IN COLOMBIA
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